IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Acce...( - Data Presented at the 21st Annua...),Health

- Data Presented at the 21st Annual Meeting of The American Society of

Pediatric Hematology/Oncology (ASPHO) Meeting -

IRVINE, Calif., May 15 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. (the Company) (Nasdaq: IDMI) today announced the presentation of updated data from a compassionate access program evaluating mifamurtide (L-MTP-PE) in patients with lung metastases as a result of the progression of osteosarcoma, a rare and often fatal bone tumor that typically affects children and young adults. The data show that L-MTP-PE in combination with other therapies is safe, well- tolerated and exhibited signs of disease control.

The compassionate access program provides L-MTP-PE treatment to patients who have either failed or cannot tolerate treatment with existing therapies compared to the Phase 3 pivotal study, which evaluated newly diagnosed patients.

"The results that we have seen to date from the Phase 3 clinical trial in patients with non-metastatic osteosarcoma are being supported in patients with lung metastases as the L-MTP-PE compassionate access experience continues to be encouraging," said Peter Anderson, M.D., Ph.D., principal investigator and professor of pediatrics, Children's Cancer Hospital at The University of Texas M. D. Anderson Cancer Center in Houston. "With a formalized protocol now in place, we can address the increasing number of requests for compassionate access to L-MTP-PE and meet the unmet needs of certain patients by providing this much needed treatment option."

Study design and findings

Twenty-nine high-risk osteosarcoma patients (ages 10 - 21) were enrolled and 27 have been treated with L-MTP-PE in the compassionate access program to date (May 8, 2008). Patients in th
'/>"/>